(Nasdaq: MIRM) today announced that on 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement ...
Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...
After hours: February 7 at 4:02:14 PM EST Loading Chart for MIRM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results